Pulmonx to Present at the Canaccord Genuity 44th Annual Growth Conference
Pulmonx (Nasdaq: LUNG), a leader in minimally invasive treatments for severe lung disease, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference in Boston. The company's management is set to present on Tuesday, August 13, 2024, at 5:00 AM PT / 8:00 AM ET.
Investors and interested parties can access a live and archived webcast of the presentation through the 'Investors' section of the Pulmonx website. This conference provides an opportunity for Pulmonx to showcase its innovations and growth strategies in the field of lung disease treatments to a wider audience of investors and industry professionals.
Pulmonx (Nasdaq: LUNG), leader nei trattamenti minimamente invasivi per gravi malattie polmonari, ha annunciato la sua partecipazione alla 44ª Conferenza Annuale sulla Crescita Canaccord Genuity a Boston. Il management dell'azienda si presenterà martedì 13 agosto 2024, alle 5:00 AM PT / 8:00 AM ET.
Gli investitori e le parti interessate possono accedere a una diretta e a una registrazione della presentazione attraverso la sezione 'Investitori' del sito web di Pulmonx. Questa conferenza offre a Pulmonx l'opportunità di mostrare le sue innovazioni e strategie di crescita nel campo dei trattamenti per le malattie polmonari a un pubblico più ampio di investitori e professionisti del settore.
Pulmonx (Nasdaq: LUNG), un líder en tratamientos mínimamente invasivos para enfermedades pulmonares severas, ha anunciado su participación en la 44ª Conferencia Anual de Crecimiento de Canaccord Genuity en Boston. La dirección de la empresa presentará el martes 13 de agosto de 2024, a las 5:00 AM PT / 8:00 AM ET.
Los inversores y partes interesadas pueden acceder a una transmisión en vivo y grabada de la presentación a través de la sección 'Inversores' del sitio web de Pulmonx. Esta conferencia brinda a Pulmonx la oportunidad de mostrar sus innovaciones y estrategias de crecimiento en el tratamiento de enfermedades pulmonares a un público más amplio de inversores y profesionales de la industria.
Pulmonx (Nasdaq: LUNG), 중증 폐 질환을 위한 최소 침습 치료의 선두주자인 Pulmonx는 보스턴에서 열리는 Canaccord Genuity 제44회 연례 성장 컨퍼런스에 참여한다고 발표했습니다. 회사 경영진은 2024년 8월 13일 화요일, 오전 5:00 PT / 오전 8:00 ET에 발표할 예정입니다.
투자자와 관심 있는 분들은 Pulmonx 웹사이트의 '투자자' 섹션을 통해 발표의 실시간 및 아카이브된 웹캐스트에 접근할 수 있습니다. 이번 컨퍼런스는 Pulmonx가 폐 질환 치료 분야에서의 혁신과 성장 전략을 더 넓은 투자자 및 산업 전문가들에게 선보일 수 있는 기회를 제공합니다.
Pulmonx (Nasdaq: LUNG), un leader dans les traitements peu invasifs pour les maladies pulmonaires graves, a annoncé sa participation à la 44e Conférence Annuelle sur la Croissance de Canaccord Genuity à Boston. La direction de l'entreprise présentera mardi 13 août 2024, à 5h00 PT / 8h00 ET.
Les investisseurs et les parties intéressées peuvent accéder à un webinaire en direct et archivé de la présentation via la section 'Investisseurs' du site web de Pulmonx. Cette conférence offre à Pulmonx l'occasion de présenter ses innovations et ses stratégies de croissance dans le domaine des traitements des maladies pulmonaires à un public plus large d'investisseurs et de professionnels du secteur.
Pulmonx (Nasdaq: LUNG), ein führendes Unternehmen im Bereich minimalinvasiver Behandlungen für schwere Lungenerkrankungen, hat seine Teilnahme an der 44. jährlichen Wachstums-Konferenz von Canaccord Genuity in Boston angekündigt. Das Management des Unternehmens wird am Dienstag, den 13. August 2024, um 5:00 Uhr PT / 8:00 Uhr ET präsentieren.
Investoren und Interessierte können über den Bereich 'Investoren' auf der Website von Pulmonx auf einen Live-Stream und aufgezeichnete Übertragungen der Präsentation zugreifen. Diese Konferenz bietet Pulmonx die Gelegenheit, seine Innovationen und Wachstumsstrategien im Bereich der Lungenerkrankungen einem breiteren Publikum von Investoren und Branchenprofis vorzustellen.
- None.
- None.
REDWOOD CITY, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced the company will present at the upcoming Canaccord Genuity 44th Annual Growth Conference in Boston. Management is scheduled to present on Tuesday, August 13, 2024, at 5:00 AM PT / 8:00 AM ET.
A live and archived webcast of the presentation will be available on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.
Contact
Brian Johnston
Gilmartin Group
investors@pulmonx.com
FAQ
When is Pulmonx (LUNG) presenting at the Canaccord Genuity Growth Conference?
Where can I watch the Pulmonx (LUNG) presentation at the Canaccord Genuity conference?
What is the focus of Pulmonx (LUNG) as a company?
Where is the Canaccord Genuity 44th Annual Growth Conference being held?
